Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. - Test2 - elhamkhani - TriplyDB

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

http://www.wikidata.org/entity/Q33551142

about

Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides Drugging MYCN through an allosteric transition in Aurora kinase A The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo Proteomic identification of Hsp70 as a new Plk1 substrate in arsenic trioxide-induced mitotically arrested cells From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists Role of endoplasmic reticulum stress in drug-induced toxicity SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer Translational progress on tumor biomarkers The function, regulation and therapeutic implications of the tumor suppressor protein, PML Traditional Chinese medicine and cancer: History, present situation, and development The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies Protein quality control in the nucleus Multivalent interactions of the SUMO-interaction motifs in RING finger protein 4 determine the specificity for chains of the SUMO Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.Cuz1/Ynl155w, a zinc-dependent ubiquitin-binding protein, protects cells from metalloid-induced proteotoxicity.Tmc1 Is a Dynamically Regulated Effector of the Rpn4 Proteotoxic Stress Response.Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment Targeting of leukemia-initiating cells in acute promyelocytic leukemia Secondary mutations as mediators of resistance to targeted therapy in leukemia Arsenic binding to proteins Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells NF-κB1 p50 promotes p53 protein translation through miR-190 downregulation of PHLPP1 Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity SYT-SSX1 (synovial sarcoma translocated) regulates PIASy ligase activity to cause overexpression of NCOA3 protein Identification of the third binding site of arsenic in human arsenic (III) methyltransferase Cardiac Glycosides Activate the Tumor Suppressor and Viral Restriction Factor Promyelocytic Leukemia Protein (PML)Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model Metabolism, toxicity and anticancer activities of arsenic compounds.A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination.Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.Properties of realgar bioleaching using an extremely acidophilic bacterium and its antitumor mechanism as an anticancer agent.A high-content screening (HCS) assay for the identification of chemical inducers of PML oncogenic domains (PODs).Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus.

P2860

Q21090848-7AECD4AD-6A32-4AC8-8FB3-469A9D9D1142 Q24303381-8FBDBCDA-0BBC-4AB2-B9A5-CCBD8AD609A2 Q24307375-CFAFEB19-74C2-43D4-ABF4-ABFFA3CB65C3 Q24317781-50C1B33E-25AD-427D-9A4A-2D6904DCA16F Q24337180-F196FC9C-B4C1-42D7-90AA-0877C87E0658 Q24605527-9DCDF9C9-30A7-4451-A987-2155E750E10A Q24623800-271D8BF4-E4AD-48F8-999B-5DD6A91DEE94 Q24631549-C3E91626-53E8-414B-AD8C-F009C6F80068 Q24632161-4249C179-4214-48AC-99AC-8F8B75230C49 Q26765518-FB310B0F-3170-485C-942A-37A0200D1C41 Q26776081-8A91EA00-2617-44DF-B057-82ABCFE44259 Q26777676-B0F3D232-8905-44A7-9553-BEF4D9D8749B Q26779358-C775C8D3-3369-4F72-B21A-E5F816B0A481 Q26786529-902238C0-63AB-417C-ADA2-D317013060C4 Q26853348-4CB62070-E7CB-41A9-BD95-AE9AFE8590C3 Q27023202-4098D0B3-49ED-44FA-B577-94AA3F53CB49 Q27680434-10026C06-0E89-420E-9F88-8428F78F375F Q27852289-EE378E9A-ADE7-49C2-BD93-845154A106DC Q27939292-9ED17DAD-6BC5-4232-8D80-99EDFF248596 Q27939530-EFFF0C9C-B3E3-4FB7-B941-E2E0AB0D1B03 Q28066236-16986859-F624-474E-ADAC-1FA9937E9B2E Q28081657-82F66D86-84B1-4BE0-A15B-2F7AEB6FE295 Q28083807-2870C892-DF8E-472C-BB30-13F63709FA50 Q28087213-CF79D912-B1EF-4CA6-95AC-09A7BAC272B6 Q28389752-C6A88B38-BE83-4699-A59D-B641D581FD7C Q28393380-94BFF9A1-5EEA-48AD-B438-2837CEF90706 Q28393889-E70F080F-B374-4EBA-B554-E9A365918C7F Q28484542-49CBCCF8-1735-4F8B-A66C-824F15DA7372 Q28542497-CDD6689D-3902-4ED8-8680-A776662DA9FE Q28568099-28DC8BD7-2F98-431A-9DC9-BD687B59DC52 Q28660913-9449C30A-38FA-495A-B416-24DFC79B2F94 Q30385919-9F4162C2-B072-48A2-B76E-16051154F033 Q33410375-AD20EAF3-D6D9-4ACA-AC06-E2204E163A42 Q33616264-063CE1BE-C980-4A11-AC6E-CE8EF9767189 Q33618916-C8A8C94D-D72E-4ABC-A5E3-C45B5CB113A3 Q33626131-9F43B82A-9F65-434E-8366-CAA2D593A88F Q33628050-BA8643D3-B069-4618-AD4C-5AE92AA99C7B Q33717094-26F31DDE-E317-4434-81DD-546C088019A3 Q33793019-32AFFC44-11AE-4A32-B13A-C3C990D88BA5 Q33815559-AD91503D-D1EA-4FCF-84CF-D15082784273

P2860

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

http://www.wikidata.org/entity/Q33551142

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Arsenic trioxide controls the ...... otein by directly binding PML.

@ast

Arsenic trioxide controls the ...... otein by directly binding PML.

@en

Arsenic trioxide controls the ...... otein by directly binding PML.

@nl

type

label

Arsenic trioxide controls the ...... otein by directly binding PML.

@ast

Arsenic trioxide controls the ...... otein by directly binding PML.

@en

Arsenic trioxide controls the ...... otein by directly binding PML.

@nl

prefLabel

Arsenic trioxide controls the ...... otein by directly binding PML.

@ast

Arsenic trioxide controls the ...... otein by directly binding PML.

@en

Arsenic trioxide controls the ...... otein by directly binding PML.

@nl

P1433

Q33551142-4537A7AD-79E4-4B1C-B130-8F4AF23D9348

P1476

Q33551142-BE1C3E63-A57C-4227-A434-29171209E724

P2093

Q33551142-09994E63-F9AF-425A-8BA6-D1D886DEB114

Q33551142-12302B26-E45B-4BC0-B0C7-262E88FACEDE

Q33551142-27DB34B6-7BC2-4B4C-BEE2-303A6929F7D9

Q33551142-2F80F335-DD24-4F66-BC2E-1AF3CBA5EE3A

Q33551142-49B05739-8D45-4CA9-A583-054084104DE5

Q33551142-513F41BE-C4E9-40D4-A394-24850FBC57E4

Q33551142-57A42071-FDA8-43B3-957B-7719EFB9861C

Q33551142-584E7912-3617-4096-B7F0-E10D13ADF54E

Q33551142-620950E0-3F0B-4FCD-95A0-621809294433

Q33551142-82C73C7E-C7FB-479A-99D5-919F9CE8B04A

P2860

Q33551142-01C8A8EC-3F0D-40CC-AE82-DCF4C23D7CD7

Q33551142-058826C8-D42E-4E9F-AF3C-BEB5E7A69164

Q33551142-08DE01CB-9647-4E07-8871-116FBFA976BB

Q33551142-0BC1477D-BB84-45FD-B4E5-9A5A923D4729

Q33551142-12C6C29C-55B2-40A7-8A76-AC85B2EB5584

Q33551142-20E8CC7E-4F96-4A1F-9A1A-45D35CEEF9A0

Q33551142-43D6B51E-303C-4E61-86BD-B7DAD0C85255

Q33551142-5A95976E-F4DC-4B17-A4A1-A9757944811E

Q33551142-5F816DF3-017D-4CC2-9DD0-3A1C44022665

Q33551142-89542A6E-166C-44F8-A737-161B854CF87B

P304

Q33551142-669AF1F8-0FC6-4137-B3B3-192CE1F03EB4

P31

Q33551142-1DB7091D-2B5C-4828-AD45-09EE9F5807CA

P356

Q33551142-B34C4B3B-31B0-410D-A331-05E02C8441D4

P407

Q33551142-330AB6AB-5EDC-4ED1-9312-C3C4D0450088

P433

Q33551142-71587588-4B41-43A5-83D2-EE8AEA34A496

P478

Q33551142-35DB1A68-7964-4AE9-8857-4EA84756628D

P50

Q33551142-2D5692D3-E2C2-41FF-AC94-B7B982752981

Q33551142-62315601-5724-4A28-9B1D-910B77834A5C

P577

Q33551142-527934BE-80AA-4BB4-8451-BC91270AD581

P5875

Q33551142-3F43629A-1392-4A08-8483-564128F135FD

P698

Q33551142-FFFFB191-2BE7-4F90-9EB6-F43C5E2D564E

P356

SCIENCE.1183424

P1433

P1476

Arsenic trioxide controls the ...... otein by directly binding PML.

@en

P2093

Ai-Xin Song

http://www.w3.org/2001/XMLSchema#string

Fei-Fei Yang

http://www.w3.org/2001/XMLSchema#string

Hong-Bin Sun

http://www.w3.org/2001/XMLSchema#string

Hong-Yu Hu

http://www.w3.org/2001/XMLSchema#string

Huai-Yu Yang

http://www.w3.org/2001/XMLSchema#string

Ji-Hui Wu

http://www.w3.org/2001/XMLSchema#string

Jian-Hua Tong

http://www.w3.org/2001/XMLSchema#string

Marion Jeanne

http://www.w3.org/2001/XMLSchema#string

Qiu-Hua Huang

http://www.w3.org/2001/XMLSchema#string

Qun-Ye Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

In vivo and in vitro characterization of the B1 and B2 zinc-binding domains from the acute promyelocytic leukemia protooncoprotein PML

RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation

PML protein isoforms and the RBCC/TRIM motif

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus

Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

Identification of arsenic-binding proteins in human breast cancer cells

Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.

How acute promyelocytic leukaemia revived arsenic.

P304

240-243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.1183424

http://www.w3.org/2001/XMLSchema#string

P407

P433

5975

http://www.w3.org/2001/XMLSchema#string

P478

328

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43080141

http://www.w3.org/2001/XMLSchema#string

P698

20378816

http://www.w3.org/2001/XMLSchema#string